×
0 0 0 0 0 0 0 0
Stockreport

Trillium Therapeutics Updates On Lead Lymphoma Trials [Seeking Alpha]

Trillium Therapeutics, Inc (TRIL)  More Company Research Source: Seeking Alpha
Last trillium therapeutics, inc earnings: 5/11 07:00 am Check Earnings Report
PDF Summary Trillium Therapeutics ( TRIL ) is a Canadian biopharmaceutical company developing fusion-proteins targeting CD47, an immune checkpoint inhibitor involved in suppression of the innate immune system (macrophages). If you are new to the CD47 story, I recommend you start here . Last week, Trillium posted updated data from early phase trials of their lead compound, TTI-621, in various lymphoma subtypes. I previously wrote about TTI-621 and the CD47 pathway and will reserve this article for the discussion of Trillium's updated results. As a reminder, TRIL is evaluating TTI-621 in ongoing trials using two methods of delivery: Intravenous (IV) Intratumoral The lead trials for TTI-621 are in diffuse large B-cell lymphoma (DLBCL) and cutaneous T-cell lymphoma (CTCL), but Trillium is also exploring TTI-621 in a variety of other hematological malignancies. A brief background of Cutaneous T-Cell Lymphoma: Lymphomas arise as cancer of the lymphocytes (white [Read more]

IMPACT SNAPSHOT EVENT TIME: TRIL
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
TRIL alerts

from News Quantified
Opt-in for
TRIL alerts

from News Quantified